MX2015011700A - Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion. - Google Patents
Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion.Info
- Publication number
- MX2015011700A MX2015011700A MX2015011700A MX2015011700A MX2015011700A MX 2015011700 A MX2015011700 A MX 2015011700A MX 2015011700 A MX2015011700 A MX 2015011700A MX 2015011700 A MX2015011700 A MX 2015011700A MX 2015011700 A MX2015011700 A MX 2015011700A
- Authority
- MX
- Mexico
- Prior art keywords
- dsm
- htf
- suppress inflammation
- epm
- inflammatory
- Prior art date
Links
- 241000605980 Faecalibacterium prausnitzii Species 0.000 title abstract 3
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 239000000284 extract Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000006041 probiotic Substances 0.000 abstract 1
- 230000000529 probiotic effect Effects 0.000 abstract 1
- 235000018291 probiotics Nutrition 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a la medicina, en particular a la inmunología y a la gastroenterología. Específicamente, se refiere a las bacterias probióticas y extractos de las mismas para uso terapéutico para el tratamiento de trastornos inflamatorios como la enfermedad inflamatoria intestinal. Se proporciona una composición que comprende como ingrediente activo la cepa Faecalibacterium prausnitzii HTF-F (DSM 26943) o un extracto de la misma que comprende la matriz polimérica extracelular (EPM, por sus siglas en inglés), y un portador, diluyente o excipiente aceptable. También se proporciona una composición antinflamatoria que comprende la EPM extraída de la cepa F. prausnitzii HTF-F, y un método para la preparación de la misma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13157830 | 2013-03-05 | ||
US201361778458P | 2013-03-13 | 2013-03-13 | |
PCT/NL2014/050131 WO2014137211A1 (en) | 2013-03-05 | 2014-03-05 | Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation. |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015011700A true MX2015011700A (es) | 2016-07-20 |
Family
ID=47827008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015011700A MX2015011700A (es) | 2013-03-05 | 2014-03-05 | Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160000838A1 (es) |
EP (1) | EP2988761A1 (es) |
JP (1) | JP2016511272A (es) |
KR (1) | KR20150134356A (es) |
CN (1) | CN105228635A (es) |
AU (1) | AU2014226633A1 (es) |
BR (1) | BR112015020819A2 (es) |
HK (1) | HK1214954A1 (es) |
MX (1) | MX2015011700A (es) |
RU (1) | RU2015137415A (es) |
WO (1) | WO2014137211A1 (es) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10548761B2 (en) * | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
US10633714B2 (en) | 2013-07-21 | 2020-04-28 | Pendulum Therapeutics, Inc. | Methods and systems for microbiome characterization, monitoring and treatment |
ITMI20131467A1 (it) * | 2013-09-06 | 2015-03-07 | Sofar Spa | Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico |
ES2661684T3 (es) * | 2014-03-03 | 2018-04-03 | Fundacio Institut D'investigació Biomèdica De Girona Dr. Josep Trueta | Método para diagnosticar cáncer colorrectal a partir de una muestra de heces humanas mediante PCR cuantitativa |
MA39710A (fr) | 2014-04-23 | 2015-10-29 | Sofar Spa | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin |
SG10201903823QA (en) | 2014-10-31 | 2019-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
EP3218524B1 (en) * | 2014-11-13 | 2020-01-08 | Institut National de la Recherche Agronomique (INRA) | Faecalibacterium prausnitzii strains for treating and preventing gastrointestinal pain |
EP3400953A1 (en) | 2014-12-23 | 2018-11-14 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
KR102523805B1 (ko) | 2014-12-23 | 2023-04-20 | 4디 파마 리서치 리미티드 | 면역 조정 |
US10465224B2 (en) | 2015-02-03 | 2019-11-05 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing and treating arthritis |
CA2979086A1 (en) * | 2015-03-12 | 2016-09-15 | The University Of British Columbia | Bacterial compositions and methods of use thereof |
EP3294308A4 (en) | 2015-05-14 | 2019-03-06 | University of Puerto Rico | PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
PT3240554T (pt) | 2015-06-15 | 2019-11-04 | 4D Pharma Res Ltd | Blautia stercosis e wexlerae para uso no tratamento de doenças inflamatórias e autoimunes |
DK3206700T3 (da) | 2015-06-15 | 2019-08-05 | 4D Pharma Res Ltd | Sammensætninger omfattende bakteriestammer |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
PT3307288T (pt) | 2015-06-15 | 2019-10-17 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
JP6529835B2 (ja) * | 2015-06-23 | 2019-06-12 | 株式会社フィス | 樹状細胞活性化剤 |
EP3130680A1 (en) * | 2015-08-11 | 2017-02-15 | Universitat de Girona | Method for the detection, follow up and/or classification of intestinal diseases |
GB201519087D0 (en) * | 2015-10-28 | 2015-12-09 | Metabogen Ab | Method for adaption |
GB201519088D0 (en) * | 2015-10-28 | 2015-12-09 | Metabogen Ab | The use of bacteria formulations |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
KR101914245B1 (ko) | 2015-11-20 | 2018-11-02 | 4디 파마 리서치 리미티드 | 박테리아성 균주를 함유한 조성물 |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
WO2017108126A1 (en) * | 2015-12-23 | 2017-06-29 | Compagnie Gervais Danone | Compositions and methods for increasing or maintaining faecalibacterium prausnitzii populations |
WO2017117142A1 (en) | 2015-12-28 | 2017-07-06 | New York University | Device and method of restoring microbiota of newborns |
FR3046934B1 (fr) * | 2016-01-25 | 2018-01-26 | Institut National De La Recherche Agronomique (Inra) | Souche de faecalibacterium prausnitzii cncm i-4573 pour le traitement et la prevention d'une inflammation gastro-intestinale |
BR112018015097A2 (pt) * | 2016-02-04 | 2018-12-26 | Universiteit Gent | composição e reatores |
MA42560B1 (fr) | 2016-03-04 | 2019-07-31 | 4D Pharma Plc | Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
MA45327A (fr) | 2016-05-13 | 2019-03-20 | Sofar Spa | Utilisation de probiotiques pour améliorer l'absorption des protéines |
WO2017210428A1 (en) * | 2016-06-01 | 2017-12-07 | Crestovo Llc | Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders |
MA45288A (fr) | 2016-06-08 | 2019-04-17 | Sofar Spa | Nouvelle utilisation médicale de probiotiques |
TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
EP3498819A4 (en) * | 2016-08-12 | 2020-04-08 | BGI Shenzhen | FAECALIBACTERIUM BUTYRICIGENERANS AND CORRESPONDING CULTURE METHOD AND APPLICATION THEREOF |
EP3511406A4 (en) * | 2016-09-06 | 2020-04-01 | BGI Shenzhen | FAECALIBACTERIUM LONGUM AND ASSOCIATED APPLICATION |
IT201600122724A1 (it) | 2016-12-02 | 2018-06-02 | Sofar Spa | Exopolysaccharides and uses thereof |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
IT201600127498A1 (it) | 2016-12-16 | 2018-06-16 | Sofar Spa | Probiotici per uso nella diverticolosi e malattia diverticolare |
EP3388069B1 (en) * | 2017-04-12 | 2019-05-01 | ETH Zurich | Consortia of living bacteria useful for treatment of microbiome dysbiosis |
US20200054697A1 (en) * | 2017-04-17 | 2020-02-20 | Baylor College Of Medicine | Commensal bacteria as novel treatment for dry eye and sjogren syndrome |
TW201907928A (zh) | 2017-05-22 | 2019-03-01 | 英商4D製藥研究有限公司 | 包含細菌品系之組成物 |
MA41708A (fr) | 2017-05-24 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
MA49425A (fr) | 2017-06-14 | 2020-04-22 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
ES2841902T3 (es) | 2017-06-14 | 2021-07-12 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas |
BR112019025948A2 (pt) | 2017-06-16 | 2020-06-30 | Biofermin Pharmaceutical Co., Ltd. | agente para prevenir ou tratar doenças e/ou inflamação associadas à gordura |
WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
CN113730443B (zh) * | 2017-09-11 | 2022-10-04 | 广州知易生物科技有限公司 | 脆弱拟杆菌及其提取物在制备防治肠易激综合征的药物中的应用 |
US11491192B2 (en) | 2018-01-09 | 2022-11-08 | The Cleveland Clinic Foundation | Treatment and prevention of pathogenic bacterial overgrowth using butyrate-producing bacteria |
WO2019139360A1 (ko) * | 2018-01-12 | 2019-07-18 | 주식회사 엠디헬스케어 | 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도 |
KR102282490B1 (ko) * | 2018-01-12 | 2021-07-28 | 주식회사 엠디헬스케어 | 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도 |
WO2020079024A1 (en) * | 2018-10-15 | 2020-04-23 | Pharmabiome Ag | Consortia of living bacteria useful for treatment of colorectal cancer |
US11751597B2 (en) | 2019-11-05 | 2023-09-12 | Alfasigma S.P.A. | Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems |
KR102169794B1 (ko) * | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도 |
KR102169795B1 (ko) | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도 |
KR20220021878A (ko) * | 2020-08-14 | 2022-02-22 | 주식회사 고바이오랩 | 피칼리박테리움 프라우스니치이 균주 및 그 용도 |
KR102185828B1 (ko) | 2020-08-26 | 2020-12-03 | 주식회사 엔테로바이옴 | 피칼리박테리움 프로스니치 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물 |
CN116615561A (zh) * | 2020-09-28 | 2023-08-18 | 希杰生物科技株式会社 | 用于诊断或治疗炎性疾病的包含微生物的组合物 |
EP4333644A1 (en) * | 2021-05-06 | 2024-03-13 | Société des Produits Nestlé S.A. | Compositions and methods using at least one of inositol, erythritol or sorbitol to enhance growth of faecalibacterium prausnitzii |
CN113797232B (zh) * | 2021-10-28 | 2023-05-26 | 南昌大学 | 具有缓解胰岛素抵抗功能的组合物及其应用 |
CN115074277B (zh) * | 2022-06-24 | 2023-09-26 | 无锡特殊食品与营养健康研究院有限公司 | 一株可缓解肥胖的普拉梭菌及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011086172A1 (en) | 2010-01-14 | 2011-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (ibd) and irritable bowel syndrome (ibs) |
NL2004201C2 (en) * | 2010-02-05 | 2011-08-08 | Friesland Brands Bv | Use of sialyl oligosaccharides to modulate the immune system. |
WO2012142605A1 (en) * | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
-
2014
- 2014-03-05 JP JP2015561299A patent/JP2016511272A/ja active Pending
- 2014-03-05 AU AU2014226633A patent/AU2014226633A1/en not_active Abandoned
- 2014-03-05 MX MX2015011700A patent/MX2015011700A/es unknown
- 2014-03-05 US US14/772,519 patent/US20160000838A1/en not_active Abandoned
- 2014-03-05 WO PCT/NL2014/050131 patent/WO2014137211A1/en active Application Filing
- 2014-03-05 EP EP14709437.9A patent/EP2988761A1/en not_active Withdrawn
- 2014-03-05 BR BR112015020819A patent/BR112015020819A2/pt active Search and Examination
- 2014-03-05 CN CN201480012892.5A patent/CN105228635A/zh active Pending
- 2014-03-05 RU RU2015137415A patent/RU2015137415A/ru not_active Application Discontinuation
- 2014-03-05 KR KR1020157027308A patent/KR20150134356A/ko not_active Application Discontinuation
-
2016
- 2016-03-14 HK HK16102935.6A patent/HK1214954A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
HK1214954A1 (zh) | 2016-08-12 |
CN105228635A (zh) | 2016-01-06 |
EP2988761A1 (en) | 2016-03-02 |
RU2015137415A (ru) | 2017-04-10 |
AU2014226633A1 (en) | 2015-09-03 |
JP2016511272A (ja) | 2016-04-14 |
BR112015020819A2 (pt) | 2017-07-18 |
US20160000838A1 (en) | 2016-01-07 |
WO2014137211A1 (en) | 2014-09-12 |
KR20150134356A (ko) | 2015-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015011700A (es) | Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion. | |
MX2022005323A (es) | Novedosos lactobacillus que tienen diversas funciones, y uso de los mismos. | |
NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
SE1550189A1 (en) | Therapeutic and prophylactic composition produced by microbiota | |
MX354047B (es) | Cepas/celulas de lactobacillus secadas por aspersion, y el uso de las mismas contra helicobacter pylori. | |
TW201613880A (en) | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole | |
UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
PH12014502243A1 (en) | Novel bacillus subtilis | |
WO2017147130A3 (en) | Direct fed microbial for prevention of shrimp disease | |
MY201921A (en) | Agent for preventing or treating fat-associated diseases and/or inflammation | |
WO2014066053A3 (en) | Method of prevention and treatment of clostridium difficile infection | |
WO2020008149A8 (fr) | Utilisation d'une souche de roseburia intestinalis pour la prévention et le traitement de l'inflammation de l'intestin | |
PH12018550110A1 (en) | Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation | |
MY186323A (en) | Lactobacillus salivarius for the treatment of mastitis | |
PH12017500637A1 (en) | Inhibitors of lysine gingipain | |
RU2012102851A (ru) | Штамм enterococcus durans вкпм в-8731, используемый для производства кисломолочных продуктов и пробиотических препаратов | |
CL2017001818A1 (es) | Bacteria de ácido láctico y su uso para el tratamiento de mastitis | |
AU2018225957A1 (en) | Composition for alleviating mental health disorder | |
WO2019054641A3 (ko) | 락토바실러스 플란타룸을 포함하는 위장관 질환의 예방 및 개선용 조성물 | |
MX2019006086A (es) | Uso de una composicion bacteriana para tratar infecciones en las patas de ungulados. | |
MX2020001501A (es) | Streptococcus australis como bioterapeuticos. | |
MY159675A (en) | Clerodane derivatives for modulation of leukotriene receptor activity and related diseases | |
RU2010150205A (ru) | Лечебно-профилактический препарат на основе антималярийного средства и пробиотика | |
WO2017160079A3 (ko) | 디케토피페라진을 유효성분으로 포함하는 전신염증질환의 치료용 약학적 조성물 |